button bars forest bayes pooled summary circles
benefit
(statisticaly significant) 		benefit (nominaly significant, not statitically demonstrated) NS not significant harm statitically significant NS harm not significant low certainty due to bias
 
deaths (OS)

mHNSCC - L1 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - all population

versus cetuximab plus platin plus 5FU
pembrolizumab alone vs. cetuximab plus platin plus 5FU 1 -17%
pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU 1 -23%

mHNSCC - L1 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - PDL1 positive

versus cetuximab plus platin plus 5FU
pembrolizumab alone vs. cetuximab plus platin plus 5FU 2 -22%
pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU 2 -37%

mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population

versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 -20%

mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative

mHNSCC - L2 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 positive

versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 -26%

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons